Basilea Pharmaceutica AG : Basilea reports 2013 half-year financials with
improved operating results
Basilea Pharmaceutica AG / Basilea reports 2013 half-year financials with
improved operating results . Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement.
*Continued improvement in financial performance
*Cash and short-term investments of CHF 262.8 million
*Guidance on isavuconazole phase 3 topline data and ceftobiprole regulatory
decision in Europe maintained for H2 2013
*Significant agreement with BARDA of up to USD 89 million funding for novel
antibiotic BAL30072 announced in H1 2013
Basel, Switzerland, August 21, 2013 - Basilea Pharmaceutica Ltd. (SIX: BSLN)
announced today financial results for the first half-year 2013 with improved
operating results, a net loss of CHF 17.3 million and cash and short-term
investments of CHF 262.8 million at the end of the period.
In the first six months of 2013, Basilea made substantial progress toward the
company's major milestones: the reporting of the isavuconazole phase 3 data
and a potential approval of ceftobiprole. In addition, the company continued
to advance its earlier-stage clinical programs.
For the antifungal isavuconazole, Basilea and its partner Astellas Pharma Inc.
are currently preparing the phase 3 data analyses of the SECURE study in
aspergillosis and the VITAL study in aspergillosis patients with kidney
impairment or with invasive fungal disease caused by emerging and often fatal
fungi. Topline data continues to be expected in H2 2013.
In Europe, the regulatory procedure of the marketing authorization application
for Basilea's broad-spectrum, anti-MRSA antibiotic ceftobiprole for the
treatment of pneumonia in the hospital is moving forward according to plan. If
the regulatory decision anticipated in H2 2013 is positive, first approvals of
ceftobiprole in Europe would be possible this year. Regarding the U.S., the
FDA indicated that their current guidelines mandating two pivotal trials per
indication are still valid. Basilea is continuing its discussions with the
Basilea's continued commitment to address the medical challenges of resistance
is demonstrated by the progress made on Basilea's two phase 1 compounds from
its research. Both drug candidates are unique and highly differentiated from
current therapies or drugs in development. Due to the broad activity of
BAL30072 against multidrug-resistant Gram-negative pathogens including those
that pose a biothreat, the Biomedical Advanced Research and Development
Authority (BARDA), a division within the U.S. Department of Health and Human
Services, entered a contract with Basilea for up to USD 89 million for the
development of BAL30072. The phase 1 development of BAL30072, which will
include combination studies with antibiotics from the carbapenem class is
First evidence of anti-tumor activity from phase 1 study data was presented in
June at the Annual Meeting of the American Society of Clinical Oncology (ASCO)
for Basilea's novel microtubule-destabilizing and vascular disrupting
anti-cancer drug, BAL101553. The program is anticipated to transition into
phase 2a of clinical development this year following establishment of the
maximum tolerated dose in the ongoing phase 1 study.
Stiefel is in the process of preparing for a U.S. filing of alitretinoin for
the treatment of severe refractory chronic hand eczema planned for 2014.
Basilea participates in the U.S. alitretinoin opportunity through a milestone
payment related to the launch of the product and royalties on future U.S.
Ronald Scott, Basilea's CEO stated: "Basilea is committed to fight the growing
global threat of resistance against established therapies. We continue to
focus on achieving our key milestones for this year including a potential
approval of our antibiotic ceftobiprole in Europe, reporting phase 3 results
for our antifungal isavuconazole and continued improvement of our financial
performance. We remain open to explore innovative collaboration and
transaction structures and we were very pleased to announce a significant
agreement with BARDA allowing for non-dilutive funding of up to USD 89 million
for our drug candidate BAL30072, which addresses Gram-negative bacterial
(In CHF million, except per share data) H1 2013 H1 2012
Product sales - 17.7
Contract revenue 20.4 13.4
Revenue from R&D services 0.1 0.1
Other income 0.1 0.0
Total operating income 20.6 31.2
Cost of sales - (5.1)
Research & development expenses (26.7) (31.6)
General & administrative/Selling, general & (11.3) (28.7)
Total operating expenses (38.0) (65.5)
Operating loss (17.4) (34.2)
Net loss (17.3) (34.6)
Net cash used for operating activities (33.7) (47.6)
Cash and short-term investments 262.8 149.0
Basic and diluted loss per share, in CHF (1.80) (3.61)
Notes: Consolidated figures in conformity with US GAAP; rounding was
The unaudited condensed consolidated financial statements of Basilea
Pharmaceutica Ltd. for the first half-year 2013 can be found on the company's
website at http://interimreport.basilea.com.
In the first six months of the financial year 2013, contract revenues
increased to CHF 20.4 million (H1 2012: CHF 13.4 million), mainly driven by
the revenue recognition associated with the agreement for Toctino® concluded
with Stiefel in July 2012. Following the transaction, Toctino® sales were
recorded by Stiefel, leading to a decrease in total operating income for the
first six months of 2013 to CHF 20.6 million (H1 2012: CHF 31.2 million).
Research and development expenses were CHF 26.7 million in the first six
months of 2013, compared to CHF31.6 million in the first six months of 2012.
This decrease is mainly due to Basilea's fulfillment of its commitment to
contribute to isavuconazole development costs in the first half of 2012.
As a consequence of the transfer of the Toctino® business to Stiefel, selling,
general and administrative expenses were significantly reduced from CHF 28.7
million in the first half of 2012 to CHF 11.3 million in the first half of
2013. Total operating expenses in the first six months of 2013 were CHF 38
million compared to CHF65.5million of the corresponding 2012 period.
As a result of these factors, and driven by Basilea's prudent financial
management, operating loss in the first six months of 2013 was reduced by
approximately 50 percent to CHF 17.4 million (H1 2012: CHF 34.2 million) and
the net loss of the period decreased to CHF 17.3 million, compared to CHF 34.6
million in the corresponding period in 2012. The basic and diluted loss per
share was reduced to CHF 1.80 for the first six months of 2013 compared to CHF
3.61 for the respective 2012 period. In the first six months of 2013, net cash
used for operating activities was CHF 33.7 million as compared to CHF 47.6
million in the first six months of 2012.
At the Ordinary General Meeting of Shareholders in April, Basilea's
shareholders approved the distribution of CHF 5.00 per share, corresponding to
CHF 48.0 million, from capital contribution reserves. The payment was made in
June. As of June 30, 2013, Basilea's combined cash and short-term investments
were CHF 262.8 million, compared to CHF 149.0 million as of June 30, 2012, and
to CHF 344.0 million (including the upfront payment of CHF 224.1 million from
Stiefel following the Toctino® agreement) as of December 31, 2012.
Total average operating expenses for 2013 are estimated to decrease to
approximately CHF7million per month primarily due to the agreement with
BARDA and continued prudent expense management. Basilea's average operating
loss in 2013 is estimated to improve to approximately CHF4million per month.
Isavuconazole - an investigational intravenous and oral broad-spectrum
antifungal, partnered with Astellas Pharma Inc., for the potential treatment
of severe invasive and life-threatening fungal infections (phase 3 clinical
Isavuconazole demonstrated in-vitro and in-vivo coverage of a broad range of
yeasts (such as Candida species) and molds (such as Aspergillus species) as
well as in-vitro activity against emerging and often fatal molds including
those that cause mucormycosis. In clinical studies isavuconazole achieved
predictable drug levels in patients, supporting reliable once-daily dosing and
a switch from intravenous to oral administration. Isavuconazole received U.S.
FDA fast-track and U.S. orphan drug designation.
Ceftobiprole - an investigational broad-spectrum intravenous antibiotic for
the potential first-line empiric treatment of severe bacterial infections
(under regulatory review in Europe for the potential treatment of pneumonia in
Ceftobiprole has demonstrated broad-spectrum activity against Gram-positive
bacteria including methicillin-resistant and vancomycin-resistant
Staphylococcus aureus (MRSA, VRSA) and penicillin-resistant Streptococcus
pneumoniae (PRSP) as well as Gram-negative pathogens, including
Enterobacteriaceae and Pseudomonas aeruginosa.
BAL30072 - an intravenous bactericidal sulfactam antibiotic against
multidrug-resistant Gram-negative bacterial infections (phase 1 clinical
BAL30072 demonstrated in-vitro and in-vivo coverage of Gram-negative pathogens
including multidrug-resistant Acinetobacterbaumannii and Pseudomonas
aeruginosa. It has robust activity against common strains of resistant
bacteria that produce antibiotic-inactivating enzymes including carbapenemases
and metallo-beta-lactamases such as the New Delhi metallo-beta-lactamase 1
(NDM-1). In addition, BAL30072 has shown additive or synergistic activity with
antibiotics from the carbapenem class. Basilea entered a contract with BARDA
for up to USD89million in funding for the development of BAL30072.
BAL101553 - an intravenous and oral small-molecule anti-cancer drug with a
dual mode of action (phase 1 clinical development)
BAL101553 directly attacks tumor cells by destabilizing the intracellular
microtubule network that is essential for cell division. In addition, it
disrupts tumor blood vessels depriving the tumor from nutrition. The drug has
shown potent anti-proliferative activity in a panel of tumor models, including
many that are not responsive to conventional microtubule-targeting agents,
such as taxanes, as a result of diverse resistance mechanisms. BAL101553 is a
water-soluble prodrug of Basilea's BAL27862, formulated as an injectable
dosage form without potentially harmful solubilizers. In addition, it is
Toctino® (oral alitretinoin) - the only licensed drug for systemic use in
adults with severe chronic hand eczema unresponsive to potent topical
Toctino® was developed and successfully brought to market by Basilea. In the
U.S., oral alitretinoin is an investigational drug in phase 3 and not yet
approved by the FDA. In July 2012, the Toctino® business was transferred to
Stiefel, a GSK company. Basilea is eligible for a milestone payment related to
the U.S. launch of alitretinoin and participation in future U.S. product
Basilea Pharmaceutica Ltd. invites you to participate in a conference call on
Wednesday, August21, 2013, 4 p.m. (CEST), during which the company will
discuss today's press release.
Dial-in numbers are:
+41 (0) 58 310 50 00 (Europe and ROW)
+1 (1) 631 570 5613 (USA)
+44 (0) 203 059 5862 (UK)
A playback will be available 1 hour after the conference call until Friday,
August 23, 2013, 6p.m. (CEST). Participants requesting a digital playback may
+41 (0) 91 612 4330 (Europe and ROW)
+1 (1) 866 416 2558 (USA)
+44 (0) 207 108 6233 (UK)
and will be asked to enter the ID 17234 followed by the # sign.
Basilea Pharmaceutica Ltd. is headquartered in Basel, Switzerland, and listed
on the SIX Swiss Exchange (SIX: BSLN). Through the fully integrated research
and development operations of its Swiss subsidiary Basilea Pharmaceutica
International Ltd., the company focuses on innovative pharmaceutical products
in the therapeutic areas of bacterial infections, fungal infections and
oncology, targeting the medical challenge of rising resistance and
non-response to current treatment options.
This communication expressly or implicitly contains certain forward-looking
statements concerning Basilea Pharmaceutica Ltd. and its business. Such
statements involve certain known and unknown risks, uncertainties and other
factors, which could cause the actual results, financial condition,
performance or achievements of Basilea Pharmaceutica Ltd. to be materially
different from any future results, performance or achievements expressed or
implied by such forward-looking statements. Basilea Pharmaceutica Ltd. is
providing this communication as of this date and does not undertake to update
any forward-looking statements contained herein as a result of new
information, future events or otherwise.
For further information, please contact:
Media Relations Investor Relations
Peer Nils Schröder, PhD Barbara Zink, PhD, MBA
Head Public Relations & Head Corporate Development
+41 61 606 1102 +41 61 606 1233
This press release can be downloaded from www.basilea.com.
Press release (PDF)
This announcement is distributed by Thomson Reuters on behalf of Thomson
The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other
applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of
information contained therein.
Source: Basilea Pharmaceutica AG via Thomson Reuters ONE
--- End of Message ---
Basilea Pharmaceutica AG
Grenzacherstrasse 487 Basel Switzerland
Listed: Freiverkehr in Börse Stuttgart,
Freiverkehr in Börse Berlin,
Open Market (Freiverkehr) in Frankfurter Wertpapierbörse,
Freiverkehr in Bayerische Börse München;
Press spacebar to pause and continue. Press esc to stop.